Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
AIT Labs and its former executives have already incurred nearly $5 million defending themselves against charges by the U.S. Department of Labor that AIT founder Michael Evans sold the company to its employees in 2009 at an inflated price.
By subtly threatening the loss of patients via a new "reference lab network," the Indianapolis-based health insurer has persuaded 63 Indiana hospitals to slash their prices for blood and tissue testing by as much as 80 percent—beyond the discounts Anthem had already negotiated with them.
Hospitals and doctors still aren’t seeing a wave of new patients because rising deductibles in patients' health plans are continuing to delay medical procedures, even though their job prospects are better than they’ve been in years.
Nurses in Indiana are underpaid, relative to their peers nationally. They are not overworked from a sheer number of hours, but the demands of hospitals nurses have spiked recently, reducing nurses' margin for caring for patients with a human touch. For a business that competes on service and, increasingly, on price, those are big problems.
IU Health had one of its most profitable years ever in 2014, as it cut staff, boosted its physician office visits and improved bill collections. But it is still hoarding cash to be ready for future cuts in reimbursement as well as future building projects.
The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.